Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PACB 
Pacific Biosciences of California (PACB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: PACB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -57.64% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 414.12M USD | Price to earnings Ratio - | 1Y Target Price 2.1 |
Price to earnings Ratio - | 1Y Target Price 2.1 | ||
Volume (30-day avg) 8370589 | Beta 2.1 | 52 Weeks Range 0.85 - 2.72 | Updated Date 06/16/2025 |
52 Weeks Range 0.85 - 2.72 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1164.47% |
Management Effectiveness
Return on Assets (TTM) -31.7% | Return on Equity (TTM) -177.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 716102622 | Price to Sales(TTM) 2.72 |
Enterprise Value 716102622 | Price to Sales(TTM) 2.72 | ||
Enterprise Value to Revenue 4.7 | Enterprise Value to EBITDA -4.15 | Shares Outstanding 300084992 | Shares Floating 297885064 |
Shares Outstanding 300084992 | Shares Floating 297885064 | ||
Percent Insiders 9.06 | Percent Institutions 66.08 |
Analyst Ratings
Rating 3.79 | Target Price 2.03 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 8 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pacific Biosciences of California
Company Overview
History and Background
Pacific Biosciences of California (PacBio) was founded in 2004. It is known for its Single Molecule, Real-Time (SMRT) sequencing technology, offering long-read sequencing solutions. Key milestones include the commercial launch of its first sequencer in 2011 and continuous advancements in accuracy and throughput.
Core Business Areas
- Sequencing Systems: Develops and manufactures DNA sequencing systems utilizing SMRT technology, designed for long-read sequencing applications. Products are used by researchers in various fields including genomics, transcriptomics, and epigenetics.
- Consumables: Supplies consumables required for operating PacBio sequencing systems, including SMRT Cells and reagents.
- Services: Offers services related to sequencing projects, including sequencing, data analysis, and consultation services.
Leadership and Structure
Christian Henry is the President and CEO. The company has a typical corporate structure with departments focusing on R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- Revio: Revio is PacBio's latest long-read sequencing system, offering high throughput and improved cost-effectiveness. Competitors include Illumina and Oxford Nanopore. PacBio states the Revio system can deliver up to 1,300 human genomes per year at a list price of $779,000 USD per system. Market share information specific to Revio is not publicly available. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies (private).
- Sequel II/IIe Systems: These platforms offer accurate long-read sequencing and are widely used for de novo genome assembly, structural variant detection, and isoform sequencing. Competitors include Illumina and Oxford Nanopore. No specific market share is known. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies (private).
- Consumables (SMRT Cells, Reagents): Required for running PacBio sequencing systems; revenue dependent on instrument usage. No specific data available on revenue for this product. Competitors are those that provide reagents for competing sequencing platforms.
Market Dynamics
Industry Overview
The genomics and sequencing market is rapidly growing, driven by advancements in technology, decreasing sequencing costs, and increasing applications in healthcare, research, and agriculture.
Positioning
PacBio specializes in long-read sequencing, offering advantages in resolving complex genomic regions and identifying structural variations compared to short-read technologies. It positions itself as a leader in high-accuracy long-read sequencing.
Total Addressable Market (TAM)
The global genomics market is expected to reach hundreds of billions of dollars. PacBio is well-positioned to capture a significant share of the long-read sequencing segment.
Upturn SWOT Analysis
Strengths
- Superior long-read sequencing technology
- High accuracy in sequencing
- Strong brand reputation in long-read sequencing
- Expanding applications in genomics
Weaknesses
- Higher cost per base compared to some short-read technologies
- Lower throughput compared to short-read sequencing
- Limited installed base compared to Illumina
Opportunities
- Increasing demand for long-read sequencing in clinical applications
- Expanding market for de novo genome assembly
- Growing adoption of isoform sequencing
- Partnerships with pharmaceutical companies and research institutions
Threats
- Competition from established sequencing companies (Illumina)
- Emergence of new sequencing technologies
- Economic downturn affecting research funding
- Pricing pressures in the sequencing market
Competitors and Market Share
Key Competitors
- ILMN
- ONT.L
Competitive Landscape
PacBio excels in long-read accuracy but faces challenges from Illumina's dominance in the overall sequencing market. Oxford Nanopore provides another alternative long-read solution.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: PacBio has experienced revenue growth driven by increased adoption of its sequencing platforms and consumables.
Future Projections: Analyst estimates project continued revenue growth driven by the Revio system and expanding applications of long-read sequencing.
Recent Initiatives: The launch of the Revio system, strategic partnerships, and expansion into new market segments.
Summary
PacBio is a leading player in long-read sequencing with advanced technology and a growing market. While it faces competition from industry giants, the increasing demand for long-read data and continuous innovation position it for future growth. However, cost and throughput limitations are areas where the company needs to improve to gain more market share. The company also needs to watch out for disruptive technologies entering the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share and financial data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pacific Biosciences of California
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2010-10-27 | President, CEO & Director Mr. Christian O. Henry M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 575 | Website https://www.pacb.com |
Full time employees 575 | Website https://www.pacb.com | ||
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.